Kymera Therapeutics Inc (NAS:KYMR)
$ 50.05 -1.84 (-3.55%) Market Cap: 3.24 Bil Enterprise Value: 2.90 Bil PE Ratio: 0 PB Ratio: 3.63 GF Score: 47/100

Kymera Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript

May 25, 2021 / 04:00PM GMT
Release Date Price: $43.68 (-4.17%)
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

Hi guys, I'm Ellie Merle. Thanks so much for joining us here at the UBS Healthcare Conference. Very happy to have Kymera Therapeutics presenting for us today at the UBS conference. With us from Kymera is Nello Mainolfi, President and CEO and Founder of Kymera. And with that, Nello, I'll pass it over to you for a presentation.

Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thanks, Ellie. Thanks for the invite, and pleasure to share a bit of an update from us today. So I'll just talk through the slides, and maybe I'll -- just to help, I'll call out the slide number as I know, you -- the audience would be able to move through the deck on their own. So maybe the best way would be to start the Slide 5, just to give a brief overview of where the company is.

So we founded Kymera in 2016. As many of you know, the goal has been to build a fully integrated biotech that would be able to take a targeted product degradation, which at that time, was still a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot